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Abstract
Curcumin (diferuloylmethane) is a phytochemical with potentObjective: 
anti-inflammatory and anti-oxidant properties, and has therapeutic potential for
the treatment of a range of inflammatory diseases, including osteoarthritis (OA).
The aim of this study was to determine whether non-toxic concentrations of
curcumin can reduce interleukin-1beta (IL-1β)-stimulated inflammation and
catabolism in an explant model of cartilage inflammation.
Articular cartilage explants and primary chondrocytes were obtainedMethods: 
from equine metacarpophalangeal joints. Curcumin was added to monolayer
cultured primary chondrocytes and cartilage explants in concentrations ranging
from 3μM-100μM. Prostaglandin E  (PGE ) and matrix metalloproteinase2 2
(MMP)-3 release into the secretome of IL-1β-stimulated explants was
measured using a competitive ELISA and western blotting respectively.
Proteoglycan (PG) release in the secretome was measured using the
1,9-dimethylmethylene blue (DMMB) assay. Cytotoxicity was assessed with a
live/dead assay in monolayer cultures after 24 hours, 48 hours and five days,
and in explants after five days.
Curcumin induced chondrocyte death in primary cultures (50μMResults: 
p<0.001 and 100μM 0.001) after 24 hours. After 48 hours and five days,p<
curcumin (≥25μM) significantly increased cell death ( 0.001 both time points).p<
In explants, curcumin toxicity was not observed at concentrations up to and
including 25μM after five days. Curcumin (≥3μM) significantly reduced
IL-1β-stimulated PG ( <0.05) and PGE  release ( 0.001) from explants,p 2 p<
whilst curcumin (≥12μM) significantly reduced MMP-3 release ( 0.01).p<
Non-cytotoxic concentrations of curcumin exert anti-catabolic andConclusion: 
anti-inflammatory effects in cartilage explants.
 
Referees
v1
published
04 Jul 2013
v2
published
20 Aug 2013
  
 1 2
report
1
report
1
report
1
report
1
 04 Jul 2013, :147 (doi: 10.12688/f1000research.2-147.v1)First Published: 2
 20 Aug 2013, :147 (doi: 10.12688/f1000research.2-147.v2)Latest Published: 2
v2
Page 1 of 17
F1000Research 2013, 2:147 Last updated: 22 JAN 2014
F1000Research
 Ali Mobasheri ( )Corresponding author: ali.mobasheri@nottingham.ac.uk
 Clutterbuck AL, Allaway D, Harris P  (2013) Curcumin reduces prostaglandin E2, matrix metalloproteinase-3 andHow to cite this article: et al.
proteoglycan release in the secretome of interleukin 1β-treated articular cartilage [v2; ref status: indexed, ] http://f1000r.es/1ks F1000Research
2013, :147 (doi: 10.12688/f1000research.2-147.v2)2
 © 2013 Clutterbuck AL et al. This is an open access article distributed under the terms of the ,Copyright: Creative Commons Attribution Licence
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the
article are available under the terms of the  (CC0 1.0 Public domain dedication).Creative Commons Zero "No rights reserved" data waiver
 This work received major financial support from the Biotechnology and Biological Sciences Research Council through theGrant information:
Industrial CASE Studentship programme (Grant Number: BBS/S/M/2006/13141) and minor financial support from the WALTHAM Centre for Pet
Nutrition. The BBSRC had no involvement in the study design, data collection, analysis and interpretation. The decision to submit the paper for
publication was not influenced by the funding bodies.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 AM is the coordinator of the D-BOARD Consortium funded by European Commission Framework 7 program (EU FP7;Competing Interests:
HEALTH.2012.2.4.5–2, project number 305815, Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases).
DA and PA are affiliated with the WALTHAM Centre for Pet Nutrition, which partially funded this study. No other competing interests were
disclosed.
 04 Jul 2013, :147 (doi: 10.12688/f1000research.2-147.v1) First Published: 2
 15 Jul 2013, :147 (doi: 10.12688/f1000research.2-147.v1)First Indexed: 2
Page 2 of 17
F1000Research 2013, 2:147 Last updated: 22 JAN 2014
Introduction
Osteoarthritis (OA) involves destruction of articular cartilage by 
a combination of mechanical injury, inflammatory mediators and 
proteolytic enzyme activity1. The high cost and potential negative 
side effects of conventional pharmacotherapy, i.e. non-steroidal 
anti-inflammatory drugs (NSAIDs), has stimulated interest in natu-
ral plant products with anti-inflammatory properties, as an alterna-
tive or adjunct to conventional therapy2. These products are being 
investigated for potential efficacy in a wide range of disorders with 
an inflammatory component, including arthritis and cancer3,4.
Curcumin (diferuloylmethane) is a polyphenol found in turmeric 
derived from the rhizomes of Curcuma longa. Curcumin is tradi-
tionally known for its powerful anti-inflammatory and anti-oxidant 
properties. At concentrations between 50 and 100μM it has been 
shown to have anti-inflammatory properties via its suppressive 
effects on I kappa B kinase (IKK) activity and consequently the 
nuclear factor-kappa B (NF-κB) signaling pathway in various cell 
types, including chondrocytes5,6. However, published work sug-
gests that curcumin is cytotoxic to both primary chondrocytes7 
and transformed chondrocyte cell lines8 at 50μM and above. Pri-
mary cells in their initial passages can be more phenotypically 
and genotypically relevant than transformed cells and are more 
applicable to the clinical setting9. Therefore, the cytotoxicity 
observed in chondrocyte cell lines may be a consequence of the 
transformation induced by the SV-40 virus. The hypothesis to be 
tested in this study was that curcumin exerts anti-inflammatory 
and anti-catabolic effects on interleukin-1beta (IL-1β)-stimulated 
cartilage explants at non-cytotoxic concentrations. Accordingly, 
we evaluated the concentrations at which a commercially available 
curcumin formulation (sourced from Sigma-Aldrich) was cytotoxic 
to primary equine chondrocytes in both monolayer and explant 
cultures and determined whether non-toxic concentrations could 
reduce proteoglycan (PG) loss and inflammatory mediator produc-
tion in an in vitro model of early OA.
Materials and methods
Tissues
Macroscopically normal articular cartilage samples were obtained 
from weight-bearing regions of the metacarpophalangeal joints of 
eleven horses of mixed breed, age and sex. The joint tissues were 
sourced from UK-based abattoirs. The joint tissues were sourced 
from UK-based abattoirs and veterinary practices. Animals were 
euthanized for non-research purposes either in accordance with 
Welfare of Animals (Slaughter or Killing) Regulations 1995 or the 
Veterinary Surgeons Act with owner consent. Approval for the use 
of clinical materials was obtained from the local Ethical Review 
Committee. Full depth cartilage from six animals was taken for 
explant culture and thin cartilage shavings were used for chondrocyte 
isolation from the remaining five animals. Cartilage samples from 
each animal were kept separate throughout. Cartilage shavings were 
aseptically harvested into low glucose Dulbecco’s modified Eagle’s 
medium (DMEM; HyClone, Thermo Fisher Scientific, Loughborough, 
UK) containing 4% penicillin/streptomycin (Sigma-Aldrich, 
Gillingham, UK) before washing in phosphate-buffered saline 
(PBS) containing 10% penicillin/streptomycin (Sigma-Aldrich, 
Gillingham, UK) for 20 minutes.
Chondrocyte isolation and culture
Thin cartilage slices were digested overnight in 0.1% collagenase 
type I (Sigma-Aldrich, Gillingham, UK) at 37°C and 5% CO2. The 
resulting cell suspension was filtered and washed before under-
going first expansion in low glucose DMEM with 2% penicillin/
streptomycin and 10% fetal bovine serum (FBS). Once confluency 
was reached, cells were passaged into 12-well plates. Only first and 
second passage confluent cells were used in this study.
Experimental design–monolayer cultures
Culture media was removed and replaced with treatment media 
(1ml/well). Control wells contained media alone (low glucose DMEM 
with 2% penicillin/streptomycin and 10% FBS), which formed the 
base for the other treatments. The NSAID carprofen (100μg/ml; 
Rimadyl®, Pfizer, Sandwich, UK) was included as a positive control, 
due to its anti-inflammatory effects on chondrocytes10. The nitric oxide 
donor, sodium nitroprusside (SNP; Sigma-Aldrich, Gillingham, 
UK) dissolved in DMEM (50mM) was used as a positive control 
for inducing cell death11. Stock solutions of curcumin (100mM; 
C1386, Sigma-Aldrich, Gillingham, UK) were prepared in cell cul-
ture grade dimethyl sulfoxide (DMSO; Sigma-Aldrich, Gillingham, 
UK) and diluted in DMEM to 1mM. From this 1mM stock, experi-
mental concentrations of curcumin (3μM, 6μM, 12μM, 25μM, 
50μM and 100μM) were prepared in DMEM and added to the 
appropriate wells. A DMSO control containing a volume equivalent 
to that found in the highest curcumin concentration was included 
on each plate to ensure that any observed effects were not due to 
the carrier solvent. Curcumin was not used to pretreat the cells and 
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5% CO2 for five days. After five days, explants were immediately 
assayed for cytotoxicity or frozen at -20°C with their corresponding 
supernatants for subsequent secretome assays.
Cytotoxicity assays–explant cultures
After five days, chondrocyte viability was assessed using the live/
dead assay. Explants were washed in PBS then incubated with 
calcein AM (2μM) and ethidium homodimer-1 (8μM) in PBS for 
30 minutes at room temperature. A confocal microscope (Leica TC 
SP2) was used to detect and measure fluorescence in 15μm z-sections 
though each explant (magnification×10).
DMMB assays
For evaluation of matrix PG release we used the metachromatic 
dye 1,9 dimethylmethylene blue (DMMB) to quantify the amount 
of sulfated glycosaminoglycans (GAGs) into the medium. Carti-
lage discs were digested in papain (Sigma-Aldrich, Gillingham, 
UK) for 16 hours. Papain-digested cartilage and their corre-
sponding supernatants were assayed in 96-well plates using the 
DMMB (Sigma-Aldrich, Gillingham, UK) method as previously 
described12. Shark chondroitin sulfate (Sigma-Aldrich, Gillingham, 
UK) was used as a standard (0–70μg). DMMB solution (200μl) 
was added to samples and standards (40μl). The plate was read 
(Multiskan Ascent, Thermo Labsystems, Basingstoke, UK) using 
Ascent Software (version 2.6, Thermo Labsystems, Basingstoke, 
UK). Total PG release was obtained from a spectrophotometric 
reading of the digested cartilage and its corresponding supernatant 
at 540nm. Percentage of PG release from the total PG content of 
the explants was calculated by dividing the supernatant value from 
the total PG release for each well.
Prostaglandin E2 (PGE2) immunoassay
A competitive immunoassay kit (R&D Systems, Abingdon, UK) 
was used to measure PGE2 release according to the manufacturer’s 
instructions. Standards (19.6–1250pg/ml), supernatant samples and 
reagents were added to a 96-well plate coated in goat anti-mouse 
polyclonal antibody and incubated for 19 hours at 6°C. The plate 
was washed and developed with 200μl substrate solution per well 
in the dark at room temperature for 20 minutes. A stop solution 
was added and the plate was read immediately (Multiskan Ascent, 
Thermo Labsystems, Basingstoke, UK) at 450nm with wavelength 
correction set at 540nm using Ascent Software (version 2.6, Thermo 
Labsystems, Basingstoke, UK).
Western blot analysis of MMP-3 release
The protein content of explant supernatants from the PG and PGE2 
assays was quantified and aliquots containing 50μg protein were 
freeze-dried overnight. The resultant pellets were resuspended in 
37μl sample buffer (NuPAGE Lithium dodecyl sulfate sample buffer 
(4×) and electrophoresed on precast 4–12% Bis-Tris 10-well gels 
(Invitrogen, Paisley, Scotland, UK) under denaturing and reducing 
conditions. Proteins were transferred to 0.45μm polyvinylidene flu-
oride (PVDF) membranes (GE Healthcare, Little Chalfont, UK) and 
blocked with 5% (w/v) non-fat milk with Tris-Buffered saline (TBS) 
containing 0.1% (v/v) Tween20 for 1 hour. Membranes were incu-
bated with a goat polyclonal antibody to matrix metalloproteinase 
3 (stromelysin) (MMP-3; Abcam, Cambridge, UK) diluted 1:1,000 in 
5% (w/v) non-fat milk at 4°C overnight. After washing, membranes 
explants prior to the addition of IL-1β. Curcumin and IL-1β were 
added simultaneously to the cultures. The plates were incubated 
at 37°C and 5% CO2. Cytotoxicity was assessed after 24 hours, 
48 hours and five days.
Cytotoxicity assays–monolayer chondrocytes
Chondrocyte viability was assessed using a commercially available 
live/dead assay (Invitrogen, Paisley, Scotland, UK) that utilizes cal-
cein AM and ethidium homodimer-1 to identify live and dead cells, 
respectively. Media was removed and centrifuged (Eppendorf, 
Eppendorf rotor) at 10,000 rpm for 25 seconds at room tempera-
ture. The resulting pellet of detached cells (if any) was washed and 
resuspended in 20μl PBS. Adherent cells in the wells were washed 
in PBS before adding 20μl of the detached cell suspension to the 
appropriate wells and incubating in calcein AM (2μM) and ethidium 
homodimer-1 (4μM) in PBS (Sigma-Aldrich, Gillingham, UK) for 
30 minutes at room temperature. Fluorescence was detected and 
captured using an inverted contrasting microscope (Leica DM IL, 
Leica Microsystems Ltd, Wetzlar, Germany) with Leica Applica-
tion Suite imaging software (Version 2.4.0 R1, Leica Microsystems 
Ltd). Six random fields of view of live and dead cells were taken per 
well (magnification×100). Live and dead cells were counted with 
ImageJ Software (National Institutes of Health, Bethesda, MD) and 
the percentage of dead cells (expressed as a percentage of the total 
number of cells present) was calculated at 24 hours, 48 hours and 
five days for each treatment.
Cartilage explant culture
Full depth cartilage shavings were cut into 3mm discs. Three discs 
per well from the same animal were placed in 24-well plates contain-
ing 1ml of culture medium (serum-free low glucose DMEM supple-
mented with 2% penicillin/streptomycin) and allowed to equilibrate 
overnight at 37°C under 5% CO2. The following day, culture media 
was replaced with fresh media before the experiment began.
Experimental design–cartilage explants
Cartilage from three animals was used for curcumin viability 
studies, and cartilage from three different animals was used for the 
remaining studies. All plates contained 1ml culture media, which 
formed the base for other treatments and acted as a control for each 
plate. Explant viability studies were performed by adding curcumin 
(12μM, 25μM and 100μM) prepared in DMEM as described above 
to the appropriate wells (one well per animal per treatment). SNP 
(50mM) was used as a positive control for cell death. The remaining 
3 wells per animal per treatment were used to determine PG release 
from unstimulated explants in response to curcumin.
Experiments aimed at assessing the anti-catabolic and anti- 
inflammatory effects of curcumin were conducted by incubating 
explants in culture media containing recombinant equine IL-1β 
(R&D Systems, Abingdon, UK) (10ng/ml) and various concentra-
tions of curcumin (3μM, 6μM, 12μM, 25μM and 50μM) prepared 
in IL-1β-treated media. Carprofen (100μg/ml) was prepared in 
IL-1β-treated media and included as a positive control. DMSO 
controls were performed previously and found to have no effect on 
PG release from both IL-1β-stimulated and unstimulated cartilage 
explants at volumes equivalent to that found in the highest curcumin 
concentration (data not shown). Plates were incubated at 37°C and 
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were incubated for two hours at room temperature with a secondary 
anti-goat antibody (1:10,000; Dako, Cambridge, UK). Membranes 
were washed and chemiluminescence detected using ECL+ on a 
Typhoon Trio+ Variable Mode Imager (both GE Healthcare, Little 
Chalfont, UK). Densitometric quantification of MMP-3 bands was 
performed using ImageJ software. Relative band intensity in com-
parison to controls was measured for samples from each animal.
Statistical analysis
Data were statistically analyzed using a one-way analysis of vari-
ance (ANOVA) with Tukey’s post hoc test (GraphPad InStat, version 
3.05, GraphPad Software Inc., La Jolla, CA). Statistical significance 
was set at p<0.05. Graphs were plotted with GraphPad Prism 
(version 4, GraphPad Software Inc).
For chondrocyte viability quantification, results are expressed 
as the mean number of dead cells per field of view per treatment 
± standard error of the mean (SEM). PG release percentage and 
PGE2 values are reported as means of combined animals ± SEM. 
For MMP-3 quantification analysis, relative intensity values were 
reported as means of 3 combined animals ± SEM.
Results
Curcumin is cytotoxic to primary chondrocytes at 25μm and 
above
Untreated controls retained a mean cell death percentage of less 
than 1% at 24 hours, 48 hours and five days (Figure 1). DMSO 
controls and the NSAID, carprofen, did not significantly increase 
cell death compared to controls at all time points. SNP effectively 
induced cell death (p<0.001, all time points) with mean cell death of 
92.95 ± 2.29% at 24 hours, 99.6 ± 0.17% at 48 hours and 100 ± 0.00% 
at five days. Curcumin significantly increased cell death compared 
to controls after 24 hours at 50μM (71.75 ± 7.25%, p<0.001) and 
100μM (99.55 ± 0.12%, p<0.001). After 48 hours a significant 
increase in toxicity compared to controls was seen at 25μM (30.67 
± 8.94%, p<0.001), 50μM (95.9 ± 0.96%, p<0.001) and 100μM 
(99.59 ± 0.18%, p<0.001). After five days, curcumin (25μM) caused 
significant increases in cell death (95.71 ± 0.72%, p<0.001), 50μM 
(99.4 ± 0.39%, p<0.001) and 100μM (100 ± 0.00%, p<0.001).
Curcumin is not cytotoxic to cartilage explant chondrocytes 
at 25μm after five days
After five days in culture without serum supplementation, explants 
retained fully viable chondrocytes as indicated by the abundant 
green staining and lack of red staining in the controls (Figure 2). 
SNP induced cell death in the explants as shown by the increased 
red staining and fewer, less vibrant green stained cells in compari-
son to the controls. Curcumin (25μM)-treated explants retained 
large numbers of green stained cells, showing no detriment to the 
viability of chondrocytes within cartilage explants after five days 
in culture. However, the large amount of red nuclei staining to the 
chondrocytes in the 100μM curcumin-treated explants indicates that 
curcumin was highly cytotoxic at this concentration.
Curcumin does not influence PG release from unstimulated 
cartilage explants
Control explants released 13.91 ± 1.13% of the total PG content of the 
cartilage into the media over five days (range: 159–414μg PG/ml of 
Figure 1. Curcumin significantly increases chondrocyte death after 
24 hours (A) at 50μM and 100μM compared to control indicated by 
*** (p<0.001). After 48 hours (B) and five days (C), curcumin (25μM) 
significantly increases chondrocyte death compared to controls. 
The nitric oxide donor, sodium nitroprusside (SNP) (50mM) also 
significantly increases chondrocyte death at 24 hours, 48 hours, and 
five days (p<0.001) compared to control. DMSO at concentrations 
found in the 100μM curcumin treatment has no effect on chondrocyte 
death. Results are expressed as the mean number of dead cells 
per field of view per treatment ± SEM. Data presented are from 5 
different animals with 2 technical replicates per animal.
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Figure 2. Three-dimensional confocal reconstructions of z stacks through cartilage explants (15μm sections) after five days in culture. 
Control (A) consists of culture media with 2% penicillin/streptomycin. Sodium nitroprusside (SNP) (50mM) (B) is a positive control for cell 
death. Treatments consist of curcumin in culture media at 25μM (C) and 100μM (D). Images are representative of explants in the treatments 
wells for each animal. Green staining indicates live metabolizing cells and red staining highlights the nuclei of dead cells. Data are from 3 
different animals, with one technical replicate per animal.
culture supernatant) (Figure 3). SNP (50mM) significantly increased 
matrix PG release to 82.01 ± 2.43% (p<0.001) after the same period. 
Curcumin did not significantly alter PG release from the explants 
after five days at 12μM, 25μM and 100μM.
 Curcumin significantly suppresses IL-1β-stimulated PG and 
PGE2 release in cartilage explants
Control explants released 11.38 ± 1.26% of the total PG content of 
the cartilage into the media over five days (range: 86–323μg PG/ml 
of culture supernatant) (Figure 4A). IL-1β (10ng/ml) significantly 
increased PG release to 44.31 ± 3.75% of total PG content com-
pared to control (p<0.001). The NSAID carprofen (100μg/ml) sig-
nificantly reduced IL-1β-stimulated PG release to 25.96 ± 3.59% 
of total PG content (p<0.01). Curcumin significantly decreased IL-
1β-stimulated PG release in the explants to 28.98 ± 2.45% at 3μM 
(p<0.05), 26.84 ± 2.49% at 6μM (p<0.01), 24.51 ± 5.42% at 12μM 
(p<0.01), 18.91 ± 4.36% at 25μM (p<0.001) and 16.05 ± 1.82% at 
50μM (p<0.001). PGE2 release into the media of unstimulated 
explants was 20.35 ± 3.67pg/ml (Figure 4B). These levels were sig-
nificantly increased (p<0.001) to 303.3 ± 73.38pg/ml by the addition 
of recombinant IL-1β (10ng/ml). The NSAID significantly attenuat-
ed this effect, reducing levels to 19.72 ± 3.74pg/ml (p<0.001). Cur-
cumin also significantly reduced IL-1β-stimulated PGE2 release to 
75.48 ± 10.68pg/ml at 3μM (p<0.001), 54.72 ± 12.41pg/ml at 6μM 
(p<0.001), 45.65 ± 13.31pg/ml at 12μM (p<0.001), 18.36 ± 2.38pg/ml 
at 25μM (p<0.001) and 26.73 ± 3.52pg/ml at 50μM (p<0.001).
Curcumin exerts dose-dependent effects on IL-1β-stimulated 
MMP-3 release in cartilage explants
Control explants released low levels of MMP-3, which were sig-
nificantly increased by the addition of IL-1β (p<0.001) (Figure 5). 
The addition of the NSAID carprofen significantly reduced IL-1β- 
stimulated MMP-3 levels (p<0.01) in all animals to near that of 
controls. Curcumin showed a dose-dependent significant effect on 
reducing the IL-1β-stimulated release at 12μM (p<0.01), 25μM 
(p<0.01) and 50μM (p<0.001). However, the concentration at 
which this reduction became apparent differed between animals. 
For example, animal C, showed a clear reduction in MMP-3 secre-
tion at curcumin concentrations of 12μM and above, whereas in ani-
mals A and B, the equivalent reduction was not seen until curcumin 
concentrations of 50μM were used. The most apparent reduction in 
MMP-3 secretion was always seen at 50μM with levels near to that 
of the controls in all animals.
Effect of curcumin on prostaglandin E2, matrix metalloproteinase-3 
and proteoglycan release in articular cartilage
11 Data Files
http://dx.doi.org/10.6084/m9.figshare.724793
150 µm
150 µm 150 µm
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Discussion
Recent research has produced conflicting results regarding the effi-
cacy and cytotoxicity of curcumin in vitro13–15. This study attempted 
to address the issue of curcumin cytotoxicity and its anti-inflammatory 
effects in equine cartilage explants and monolayer chondrocyte 
cultures. The results of this investigation suggest that curcumin 
induces chondrocyte death at concentrations of 25μM and above in 
monolayer chondrocytes after 48 hours and five days.
The cytotoxic effects of curcumin (50μM) have been observed and 
documented in other cell types, notably tumor cell lines16. Induc-
tion of apoptosis through cytochrome c release and subsequent 
caspase activation is thought to be a key chemopreventive effect 
of curcumin in cancer studies17. In agreement with this, curcumin 
(50μM) has also been shown to reduce the viability of an immortal-
ized human chondrocyte cell line after 24 hours8. The results from 
this study suggest that this is also the case with primary equine 
chondrocytes. However, a recent study on primary human chon-
drocytes found that curcumin (50μM) did not reduce cell viability 
and successfully inhibited IL-1β-induced cytotoxicity as demon-
strated by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay18. This could be due to species-specific differ-
ences in chondrocyte susceptibility to curcumin, or equally likely, 
the different sources of curcumin used. This highlights the impor-
tance of assessing cytotoxicity alongside anti-inflammatory assays, 
with the same formulation of curcumin in each individual study.
Figure 3. Effect of curcumin on proteoglycan (PG) release from 
unstimulated cartilage explants. Control column indicates cartilage 
discs incubated in the culture medium alone. Values are reported 
as the mean of three animals per treatment ± SEM. Data are from 
3 different animals, with three technical replicates per animal. 
Significance compared to control is indicated by *** (p<0.001). 
Sodium nitroprusside (SNP) (50mM) significantly increases PG 
release compared to control (p<0.001). Curcumin does not alter 
PG release from the explants compared to control at concentrations 
of 12μM, 25μM or 50μM. PG loss is expressed as sulfated 
glycosaminoglycan (GAG) release. 
Figure 4. Effect of curcumin on PG release (A) and prostaglandin 
E2 (PGE2) (B) from interleukin (IL)-1β-stimulated cartilage explants 
(dark grey columns) (n=3). Control (light grey column) indicates 
cartilage discs incubated in the culture medium alone. Values are 
reported as the mean of three animals per treatment ± SEM. Data are 
from 3 different animals, with three technical replicates per animal. 
Significance compared to IL-1β is indicated by * (p<0.05), ** (p<0.01) 
and *** (p<0.001). IL-1β significantly increases proteoglycan (PG) 
(p<0.001) and PGE2 (p<0.001) release compared to control. The 
non-steroidal anti-inflammatory drug (NSAID) carprofen (100μg/ml) 
significantly reduces IL-1β-stimulated PG (p<0.01) and PGE2 
(p<0.001) release. Curcumin significantly reduces IL-1β-stimulated 
PG release at 3μM (p<0.05), 6μM (p<0.01), 12μM (p<0.01), 25μM 
(p<0.001) and 50μM (p<0.001). IL-1β-stimulated PGE2 release is 
also significantly reduced at all curcumin concentrations (p<0.001). 
PG loss is expressed as sulfated glycosaminoglycan (GAG) release.
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from monolayer cultures may not reflect cytotoxic changes in 3- 
dimensional culture models and explant cultures.
For the purposes of addressing cytotoxicity in this study, a live/
dead stain was selected to detect chondrocyte death as it can quickly 
provide qualitative and quantitative data on both monolayer and 
3-dimensional chondrocyte cultures. The method does not distin-
guish between apoptosis and necrosis as the mode of cell death and 
although this information was not required for this study, it could be 
a useful addition to future studies. It should be noted here that cell 
death in monolayer cells can be underestimated, as dead cells can 
detach and be removed with the media. However, this risk was 
mitigated by centrifuging the discarded media so that the resulting 
In contrast to the monolayer cell cultures, curcumin (25μM) did 
not induce cytotoxicity in chondrocytes within cartilage explants 
after five days, although toxicity was seen at 100μM. Within car-
tilage, chondrocytes are embedded in a complex extracellular 
matrix (ECM) across which diverse diffusion gradients and fluid 
flow occurs19. This could account for the differing toxicity threshold 
between monolayer cultures and explants. Chondrocytes are more 
vulnerable to cell death when they are no longer encased within a 
matrix, as cell adhesion and integrin attachments are important fac-
tors in promoting cell survival20. Thus, without a protective ECM, 
monolayer chondrocytes may be more exposed and susceptible to 
external agents in the culture media than those within explants, as 
has been shown with bupivacaine21. Therefore, cytotoxicity data 
Figure 5. Western blot images and quantifying graphs of matrix metalloproteinase (MMP)-3 in the cartilage explant supernatants from 
three animals (A, B, and C). The lane on the left of the images shows the molecular weights (MW) of standard markers (Invitrogen, Paisley, 
Scotland, UK) in kilodaltons (kDa). Graph D shows the relative intensity of bands from all three animals with labeled treatment axes. Values 
are reported as the mean of three animals per treatment ± SEM. Significance compared to interleukin (IL)-1β is indicated by ** (p<0.01) 
and *** (p<0.001). All lanes contain equal volumes of protein (50μg protein per lane). Unstimulated cartilage explants release low levels of 
MMP-3 as shown by the controls in lane 1. Secretion of MMP-3 from explants is significantly increased (p<0.001) by IL-1β (10ng/ml) (Lane 
2). The non-steroidal anti-inflammatory drug (NSAID) carprofen (100μg/ml) (Lane 3) significantly reduces IL-1β-stimulated MMP-3 secretion 
(p<0.01) to near control levels. Curcumin at concentrations of 3μM (Lane 4) and 6μM (Lane 5) does not significantly reduce IL-1β-stimulated 
MMP-3 release from the explants. However, a significant reduction is observed at 12μM (p<0.01) (Lane 6), 25μM (p<0.01) (Lane 7) and 50μM 
(p<0.001) (Lane 8) from explants in a dose dependent manner. The extent of reduction differs between animals (one technical replicate was 
used from each animal).
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reduced MMP-3 secretion at concentrations as low as 12μM in 
some animals, and as high as 50μM in others, suggesting some 
animal-to-animal variability. However, when treated with 50μM 
curcumin, IL-1β-stimulated explants from all the animals used 
secreted MMP-3 levels that were lower than, or equivalent to, 
unstimulated control explants. This is in agreement with a pre-
vious study showing that curcumin (50μM) effectively reduced 
MMP-3 levels in IL-1β-stimulated-human chondrocyte lysates37. 
However, lower curcumin concentrations have been reported 
as effective in cartilage from human OA patients post mor-
tem, where curcumin reduced MMP-3 release into the media of 
IL-1β-stimulated chondrocytes at 15μM and in cartilage explants 
at 5μM38. Many variables may account for the difference in 
effective curcumin concentrations, including individual variation, 
pre-existing joint pathology and the explant model used. It should 
be noted that many MMPs, including collagenases, matrilysin 
(MMP-7), and other stromelysins (e.g. MMP-10), are involved 
in osteoarthritic cartilage degradation39–41. Thus, the reduction 
in MMP-3 secretion would contribute to, but not totally account 
for, the reduction in PG release from IL-1β-stimulated cartilage 
explants.
The reported anti-inflammatory effects of curcumin have stimulated 
increasing interest in its potential for the treatment of inflamma-
tory disorders42. Curcumin is thought to exert its anti-inflammatory 
effects through reducing COX-143, COX-244, and microsomal PGES 
expression16, thus preventing PGE2 release. This is most likely due 
to its inhibitory effect on the upstream NF-κB-signaling pathway, 
which promotes PGE2 production via upregulating the COX and 
PGES genes45. In this study, curcumin at concentrations of 3μM 
and over significantly reduced PGE2 release in response to equine 
IL-1β (10ng/ml). This anti-inflammatory effect is consistent with 
previous work in other cell culture models, such as rat peritoneal 
macrophages where curcumin (10μM) inhibited PGE2 release by 
45%46, and in BV2 microglial cells where curcumin (10μM and 
20μM) significantly reduced PGE2 release in response to lipopol-
ysaccharide (LPS) (0.5μg/ml)47. The reduction in PGE2 levels in 
response to IL-1β in our study may be attributed to the inhibitory 
effects of curcumin on the NF-κB pathway. Curcumin (50μM) has 
been shown to inhibit various steps of the NF-κB pathway, such as 
IL-1β-dependent phosphorylation of p65; nuclear-translocation 
of p65; and IκBα phosphorylation in IL-1β-stimulated human 
chondrocytes6. Thus by inhibiting NF-κB, curcumin prevents the 
downstream inflammatory effects of COX-2 expression and PGE2 
synthesis.
Although curcumin was able to effectively attenuate the catabolic 
effects of IL-1β in this model, many other biochemical and biome-
chanical factors are capable of inducing cartilage inflammation and 
degeneration; these include compressive stress caused by overload-
ing or traumatic injury of the joint48,49 and different cytokines such as 
tumor necrosis factor alpha (TNF-α) alone and in combination with 
oncostatin M (OSM)50. Further studies are required to determine 
whether curcumin can reduce inflammation and degeneration gen-
erated by combinations of different catabolic stimuli.
The anti-inflammatory and anti-catabolic effects of curcumin shown 
in this study support the existing evidence that curcumin may 
be supportive to joint health13–15. However, the bioavailability of 
pellet of detached cells could be resuspended and returned to the 
well before the live/dead stain reagents were added.
Once the uppermost observed safe level of curcumin was determined, 
the effect of curcumin on cartilage catabolism and inflammation was 
examined in explants. No significant effect of curcumin alone on 
matrix PG release from normal cartilage explants at both safe and 
toxic concentrations was observed. This suggests that curcumin 
does not alter the basal level of PG released from unstimulated 
cartilage explants in culture, even at cytotoxic concentrations. 
Interestingly, in these unstimulated explants, the two treatments 
that caused cell death had different effects on PG release: SNP 
(50mM) caused extensive PG loss into the media whereas curcum-
in (100μM) did not alter PG release compared to controls. PG loss 
does not directly lead to cell death in cartilage explants22, thus the 
PG loss caused by SNP is unlikely to be primarily a consequence 
of cell death. SNP generates nitric oxide (NO), ceramide and cya-
nide, which aside from causing apoptosis, reduces proteoglycan 
and collagen synthesis by chondrocytes and increases inflammato-
ry mediator production and MMP activity23–25 resulting in cartilage 
matrix loss. Conversely, although curcumin (100μM) induces cell 
death, it is likely to involve a mechanism that does not induce the 
release of any proteases. Curcumin is known to reduce the release 
of inflammatory mediators, MMPs and NO6,26. We have shown in 
this study that cytotoxic levels of curcumin reduce IL-β-stimulated 
PGE2 and MMP-3 release. The reduced production of inflamma-
tory mediators and catabolic enzymes suggests that it is unlikely 
to induce extensive PG loss as demonstrated in both IL-1β-treated 
and untreated cartilage explants in this study.
Curcumin at 3μM and above significantly reduced PG loss from 
IL-1β-stimulated explants. This reduction in PG loss was seen at 
concentrations that were non-detrimental to chondrocyte viability 
in explants (i.e. 25μM and under) as well as cytotoxic concentra-
tions (100μM). Previously, we observed that curcumin (100μM) 
significantly reduced human IL-1β-stimulated PG release from 
cartilage explants, but this effect was not seen at 10μM27. The dif-
ferences in concentration efficacy between these two studies may 
be linked to individual variation or the source of cytokines used. 
Our previous study used human IL-1β on equine explants, where-
as the current study used equine recombinant IL-1β. Despite a 
fairly conserved sequence homology between species, the use of 
species-specific IL-1β is more representative of the in vivo situa-
tion and thus may explain the difference in results seen between 
studies.
The involvement of pro-inflammatory cytokines and MMPs in 
OA is well documented28,29. MMP-3, also known as stromelysin, 
is produced by chondrocytes in OA cartilage tissue30. MMP-3 
gene expression is up-regulated in response to IL-1β stimula-
tion in chondrocytes31. Similarly, MMP-3 protein expression is 
increased by the addition of IL-1β to cartilage explants32. MMP-3 
was chosen as a marker of cartilage degradation in this study, as 
there is convincing evidence for a role for MMP-3 in cartilage 
destruction in OA. MMP-3 is induced by IL-1β in joint inflam-
mation, and has the capacity to degrade collagens, proteoglycans 
and activate other procollagenases33. MMP-3 and two other MMPs 
including MMP-1 and MMP-13 can also cleave the aggregating 
proteoglycan aggrecan at the interglobular domain34–36. Curcumin 
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curcumin is thought to be relatively low51 and efforts to determine 
whether chemically modified versions of curcumin may improve 
bioavailability merit further investigation13,52.
In summary, although this study found that curcumin at concentra-
tions of 25μM and above is cytotoxic to monolayer chondrocytes 
after five days in culture, lower concentrations effectively antagonize 
PG and PGE2 release in vitro and exert a potent anti-inflammatory 
effect on cartilage explants treated with IL-1β. Achieving micro-
molar concentrations of curcumin in the synovial joint, or to the 
pericellular matrix of chondrocytes embedded deep within the 
avascular articular cartilage is highly unlikely. Controversial issues 
associated with the metabolism and bioavailability of curcumin 
highlight the need for caution when extrapolating in vitro data for 
translational research and clinical trials. Nevertheless, our results 
to date suggest that a commercially available curcumin formula-
tion at 12μM and below, has no obvious cytotoxic effects on pri-
mary chondrocytes after five days in culture. More importantly, 
concentrations as low as 3μM were able to effectively reduce IL-
1β-stimulated cartilage degradation and inflammatory mediator 
production. This study supports existing evidence to suggest that 
curcumin may be a suitable adjunct to conventional drugs for the 
treatment of inflammatory and degenerative disorders such as OA. 
If curcumin is to be used as an anti-inflammatory supplement, fur-
ther research is required to establish its bioavailability and physi-
ologically relevant serum and synovial concentrations in vivo in 
humans and animals.
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Nottingham and the University of Bradford, UK
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The authors wish to thank Dr. Grundmann for his insightful comments and for approving the
second version of the paper. 
 No competing interests were disclosed.Competing Interests:
Referee Responses for Version 1
 Stefan Toegel
Medical University of Vienna, Vienna, Austria
Approved: 15 July 2013
 15 July 2013Referee Report:
In the present report, Clutterbuck and co-workers describe the cytotoxic and anti-inflammatory effects of
curcumin in equine cartilage explants and chondrocytes. Their study demonstrates that curcumin is a
potent inhibitor of IL1ß-induced PGE2, MMP3 and GAG release from cartilage at non-toxic
concentrations. I found this article very interesting to read as it highlights important aspects of practical
relevance for research on curcumin activity in cartilage. I do have a few remarks that might help to
somewhat improve the manuscript.
Suggested revisions 
The Figure legends should include detailed information on the number of technical and biological
replicates used. 
The Methods should clarify whether curcumin and IL1ß were added simultaneously to the
cells/explants or whether curcumin was used to “pretreat” the cells/explants prior to the addition of
IL1ß.
In the results section the authors state: “The most apparent reduction in MMP-3 secretion was
always seen at 50μM with levels near to that of the controls in all animals.” This issue is also
discussed in the 'discussion section later on. However, as Figure 1 demonstrates, significant
cytotoxic results are expected from applying this concentration. The results should therefore be
discussed in light of this finding.
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discussed in light of this finding.
A reference protein (loading control) should be included in the Western Blot images in Figure 5.
Did the authors check the Gaussian distribution of the data before applying ANOVA statistics?
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
1 Comment
Author Response
, School of Veterinary Medicine and Science, Jointly appointed at the University ofAli Mobasheri
Nottingham and the University of Bradford, UK
Posted: 11 Aug 2013
  Response to Dr. Stefan Toegel  
In response to Dr. Stefan Toegel’s review, we have included detailed information on the
number of technical and biological replicates used in the revised figure legends.
Fig 1 - 5 biological replicates (animals) and 2 replicates per animal 
Fig 2 - 3 biological replicates (animals) and 1 replicate per animal 
Fig 3 - 3 biological replicates (animals) as already stated in the legend and 3 replicates per
animal 
Fig 4 - 3 biological replicates (animals) as already stated in the legend and 3 replicates per
animal
Fig 5 - 3 biological replicates (animals) as already stated in the legend and 1 replicate per
animal 
Curcumin was not used to “pretreat” the cells/explants prior to the addition of IL-1β.
Curcumin and IL-1β were added simultaneously. The revised Materials and methods
section now clarifies the fact that curcumin and IL-1β were added simultaneously to the cells
and explants. 
This is a very good point. However, we are mainly talking about curcumin at 25uM and
under being non cytotoxic, yet effective. 
We did not include a reference protein in the western blots, as there are no proteins that can
effectively be used as reference proteins in the secretome. However, we did perform a
protein assay to ensure that equal quantities of protein were loaded on the polyacrylamide
gels before western blotting.
No, we did not check the Gaussian distribution of the data before applying ANOVA
statistics.
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 Oliver Grundmann
University of Florida, Gainesville, FL, USA
Approved: 09 July 2013
 09 July 2013Referee Report:
This interesting article submitted by Clutterbuck  is a well written and designed research paper. I doet al.
have a few comments that would help to clarify the research for readers.
 
Suggested revisions:
 
In the methods section the authors should clearly state how many repetitions have been used for
each experiment and each condition – this is not clear at times. Presumably at least 3 repetitions
per assay per condition were made in order to derive the statistics but this should be specified. 
In figures 3 and 4A, the % of proteoglycan release is mentioned and graphed – how is this related
to the total PG content if the variability appears to be rather high from the 80s to over 300 μg/mL?
This needs to be clarified. 
In figure 5, did the authors use a reference protein to ensure that the same total protein content
was used for each band? If so, this should be included as a reference in Figure 5.
In the discussion section, the authors mention that curcumin in different preparations can present
with varying effects. Since curcumin is a pure substance isolated from Curcuma longa, it will have
the same chemical properties and therefore – given that it is properly dissolved like in this study
using DMSO in non-toxic concentrations – then it should not be different from any other study. If
the authors refer to a Curcuma longa extract then it would be a different issue worth discussing.
Furthermore, and of great importance, the authors briefly mention the low bioavailability of
curcumin  in humans – how does that compare to the concentrations that were used in thesein vivo
experiments? What would be a good comparison blood concentration one could expect in humans
after oral application of curcumin? This should be included in the discussion section to provide the
reader with some perspective.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
1 Comment
Author Response
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, School of Veterinary Medicine and Science, Jointly appointed at the University ofAli Mobasheri
Nottingham and the University of Bradford, UK
Posted: 11 Aug 2013
  Response to Dr. Oliver Grundmann
In response to Dr. Grundmann’s comments we have added some additional points to clarify
the research for the readers. In response to both reviewers we have included the number of
technical and biological replicates used. At least 3 biological replicates were used in each
experiment and some assays included multiple technical replicates. 
Regarding the proteoglycan release data, it can be argued that such results should be
expressed as micrograms of glycosaminoglycan (GAG) per milligram of cartilage to account
for variation in explant weight, as previously shown as either wet weight or dry weight.
However, percentage GAG release has been used in previous studies and was selected as
a more accurate measure. Expressing the results as a percentage means that the
proportion of GAG released was quantified in relation to the total amount of GAG in each
explant. Obviously, this is not the case when discussing the PGE  results but although the2
data are expressed as a total value of PGE  per ml, pilot studies showed that the explant2
weight variation was low, with a mean wet weight (± SEM) of 4.24 ± 0.10mg. Thus, the
explants were of a similar weight and size. 
As highlighted in our response to Dr. Toegel, we did not include a reference protein in the
western blots, as there are no reliable secreted proteins that can effectively be used as a
loading control in secretome samples. Instead, we performed a protein assay to ensure that
protein was equally loaded on the gels before western blotting. 
We agree with Dr. Grundmann’s assertion that pure curcumin isolated from Curcuma longa
should have identical effects when dissolved in DMSO in cell culture studies as it should
retain the same chemical properties. The curcumin used in this study is a widely used
formulation from Sigma-Aldrich with a reported purity of approximately 70%. It could be
argued that only pure curcumin should have been tested to ensure that the effects seen in
the models were from curcumin alone. However, the curcumin used in this manuscript, has
been used by several investigators on other cell types, and so there was a benefit in using it
to enable comparisons with the published literature. It should be noted here that many
commercially available curcumin preparations, including the preparation used in this
manuscript, are often a mixture of three curcuminoids; curcumin (also known as
diferuloylmethane), demethoxycurcumin and bisdemethoxycurcumin. Therefore, the term
‘curcuminoid’ may be more appropriate to describe curcumin preparations of this nature.
However, for comparative purposes with published studies that use the term ‘curcumin’, and
in the absence of analytical data determining the activity of various fractions of the
curcuminoid constituents in the curcumin used in this study, the term curcumin was used to
describe the commercially available formulation. We hope that Dr. Grundmann will be
satisfied with this explanation. 
Finally, we wish to refer Dr. Grundmann to three recent review articles in which the
corresponding author has addressed the issue of low curcumin bioavailability  inin vivo
human subjects (please refer to citations 13, 14 and 15 in this paper). These reviews have
been cited in this manuscript. The range of concentrations used in these experiments was
indeed higher than those that can be achieved . However, the pharmacokinetic profilein vivo
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been cited in this manuscript. The range of concentrations used in these experiments was
indeed higher than those that can be achieved . However, the pharmacokinetic profilein vivo
of curcumin is characterized by its low serum concentration and limited tissue distribution.
The available clinical data supports the notion that the serum concentration of curcumin
peaks 1-2 hours after an oral dose in human subjects with peak serum concentrations of
0.5, 0.6 and 1.8 micromolar at doses of 4, 6 and 8 g/day. These are the most reliable serum
concentrations that one might expect in humans after oral consumption of curcumin.
Strategies to improve bioavailability include the use of sustained released drug delivery
systems, liposome delivery systems and nanoparticles. The possibility is the intraarticular
injection of biologically active doses of curcumin to metabolising chondrocytes and
synoviocytes. However, there are no studies that have attempted intra-articular injection of
high doses of curcumin.
 The authors have no competing interests to declare.Competing Interests:
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